Mylan Laboratories
Executive Summary
Firm signs a licensing agreement for antifungal sertaconazole with Ferrer Internacional of Barcelona. The compound has potential against yeast, dermatophytes, pathogenic filament fungi and dimorphic fungi as well as gram-positive bacteria and trichomonas, Mylan says. In April 1993, Mylan and Ferrar signed their first licensing agreement, for dotarizine. Mylan predicts that it will file an IND for dotarizine for treatment of migraine by the end of the year